Not provided
Not provided
Not provided
Not provided
Not provided
Sufficient data has been obtained to meet current objectives
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of this trial is to investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of CVL-936 following single ascending oral doses in healthy subjects.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Active Comparator: Group 1 Period 1: 0.5mg CVL-936 | Active Comparator | Oral suspension/solution |
|
| Placebo Comparator: Group 1 Period 1: 0.5mg Matching Placebo | Placebo Comparator | Matching Placebo; Oral suspension/solution |
|
| Active Comparator: Group 1 Period 2:TBD mg CVL-936 | Active Comparator | Oral suspension/solution |
|
| Placebo Comparator: Group 1 Period 2:TBD mg Matching Placebo | Placebo Comparator | Matching Placebo; Oral suspension/solution |
|
| Active Comparator: Group 1 Period 3:TBD mg CVL-936 | Active Comparator | Oral suspension/solution |
|
| Placebo Comparator: Group 1 Period 3:TBD mg Matching Placebo | Placebo Comparator |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| CVL-936 | Drug | CVL-936 |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Subjects with reported Treatment Emergent Adverse Events (TEAEs) | At the end of Period 3 (30 Days) | |
| Number of Subjects with Clinically significant changes in Electrocardiogram measures (PR, RR, QT and QTcF) | At the end of Period 3 (30 Days) | |
| Number of Subjects with Clinically meaningful changes in Vital signs (Systolic and Diastolic blood pressures, heart rate, respiratory rate and body temperature) | At the end of Period 3 (30 Days) | |
| Number of Subjects with Clinically significant changes in laboratory measures | Number of subjects with clinically significant changes in hematology, serum chemistry and urinalysis will be reported | At the end of Period 3 (30 Days) |
| Change from baseline of the Columbia-Suicide Severity Rating Scale (C-SSRS) | The C-SSRS rates an individual's degree of suicidal ideation (SI) on a scale, ranging from "wish to be dead" to "active suicidal ideation with specific plan and intent." The scale identifies SI severity and intensity, which may be indicative of an individual's intent to commit suicide. C-SSRS SI severity subscale ranges from 0 (no SI) to 5 (active SI with plan and intent). | At the end of Period 3 (30 Days) |
| Change from Baseline of Simpson-Angus Scale (SAS) Results | Evaluating Extrapyramidal symptoms using the SAS. The SAS consists of a list of 10 symptoms of parkinsonism (gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, head rotation, glabella tap, tremor, salivation, and akathisia). Each item is rated on a 5-point scale, with a score of 0 representing absence of symptoms and a score of 4 representing a severe condition. The SAS total score is the sum of the scores for all 10 items. |
Not provided
Not provided
Inclusion Criteria:
1. Healthy male subjects and female subjects of nonchildbearing potential, ages 18 to 50 years
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Matt Leoni, MD | Cerevel Therapeutics, LLC | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hassman Research Institute | Marlton | New Jersey | 08053 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D019966 | Substance-Related Disorders |
| ID | Term |
|---|---|
| D064419 | Chemically-Induced Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
A sample size of 9 subjects per cohort has been chosen based on the need to minimize exposure of humans to CVL-936 and PF-06815106 and the requirement to provide adequate safety, tolerability, and PK information at each dose. Each cohort will be conducted as a crossover design with 3 periods and each cohort will have up to 6 subjects receiving CVL-936 and 3 subjects receiving placebo within each period, with a total of approximately 18 subjects if 2 cohorts complete or a total of approximately 27 subjects if 3 cohorts complete.
Not provided
Not provided
Not provided
Matching Placebo; Oral suspension/solution
|
| Active Comparator: Group 2 Period 1:TBD mg CVL-936 | Active Comparator | Oral suspension/solution |
|
| Placebo Comparator: Group 2 Period 1:TBD mg Matching Placebo | Placebo Comparator | Matching Placebo; Oral suspension/solution |
|
| Active Comparator: Group 2 Period 2:TBD mg CVL-936 | Active Comparator | Oral suspension/solution |
|
| Placebo Comparator: Group 2 Period 2:TBD mg Matching Placebo | Placebo Comparator | Matching Placebo; Oral suspension/solution |
|
| Active Comparator: Group 2 Period 3:TBD mg CVL-936 | Active Comparator | Oral suspension/solution |
|
| Placebo Comparator: Group 2 Period 3:TBD mg Matching Placebo | Placebo Comparator | Matching Placebo; Oral suspension/solution |
|
| Active Comparator: Group 3: TBD mg CVL-936 | Active Comparator | Oral suspension/solution |
|
| Placebo Comparator: Group 3: TBD mg Matching Placebo | Placebo Comparator | Matching Placebo; Oral suspension/solution |
|
| Matching Placebo | Drug | Placebo matching CVL-936 |
|
| At the end of Period 3 (30 Days) |
| Change from Baseline of Abnormal Involuntary Movement Scale (AIMS) Results | The AIMS assessment consists of 10 items describing symptoms of dyskinesia. Facial and oral movements (items 1 through 4), extremity movements (items 5 and 6), and trunk movements (item 7) are observed unobtrusively while the subject is at rest, and the investigator also makes global judgments on the subject's dyskinesias (items 8 through 10). Each item is rated on a 5-point scale, with a score of 0 representing absence of symptoms (for item 10, no awareness), and a score of 4 indicating a severe condition (for item 10, awareness, severe distress). In addition, the AIMS includes 2 yes/no questions that address the subject's dental status. The AIMS Movement Rating Score is defined as the sum of items 1 through 7 (ie, items 1 through 4, facial and oral movements; items 5 and 6, extremity movements; and item 7, trunk movements). | At the end of Period 3 (30 Days) |
| Change from Baseline of Barnes Akathisia Rating Scale (BARS) Results | Evaluating Extrapyramidal symptoms using the BARS. The BARS consists of 4 items related to akathisia: objective observation of akathisia by the investigator, subjective feelings of restlessness by the subject, subjective distress due to akathisia, and global clinical assessment of akathisia. The first 3 items are rated on a 4-point scale, with a score of 0 representing absence of symptoms and a score of 3 representing a severe condition. The global clinical evaluation is made on a 6-point scale, with a score of 0 representing absence of symptom and a score of 5 representing severe akathisia. | At the end of Period 3 (30 Days) |